JP7661235B2 - 環状リン酸エステル化合物 - Google Patents
環状リン酸エステル化合物 Download PDFInfo
- Publication number
- JP7661235B2 JP7661235B2 JP2021559729A JP2021559729A JP7661235B2 JP 7661235 B2 JP7661235 B2 JP 7661235B2 JP 2021559729 A JP2021559729 A JP 2021559729A JP 2021559729 A JP2021559729 A JP 2021559729A JP 7661235 B2 JP7661235 B2 JP 7661235B2
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- compound
- group
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025060882A JP2025106352A (ja) | 2019-04-22 | 2025-04-02 | 環状リン酸エステル化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837137P | 2019-04-22 | 2019-04-22 | |
| US62/837,137 | 2019-04-22 | ||
| PCT/US2020/029149 WO2020219464A1 (en) | 2019-04-22 | 2020-04-21 | Cyclic phosphate compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025060882A Division JP2025106352A (ja) | 2019-04-22 | 2025-04-02 | 環状リン酸エステル化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022529321A JP2022529321A (ja) | 2022-06-21 |
| JP2022529321A5 JP2022529321A5 (cg-RX-API-DMAC7.html) | 2023-04-26 |
| JP7661235B2 true JP7661235B2 (ja) | 2025-04-14 |
Family
ID=72941350
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559729A Active JP7661235B2 (ja) | 2019-04-22 | 2020-04-21 | 環状リン酸エステル化合物 |
| JP2025060882A Pending JP2025106352A (ja) | 2019-04-22 | 2025-04-02 | 環状リン酸エステル化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025060882A Pending JP2025106352A (ja) | 2019-04-22 | 2025-04-02 | 環状リン酸エステル化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220220145A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3966221A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7661235B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20260062967A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113939526A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020263283B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3136954A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX428883B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020219464A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019207626B2 (en) | 2018-01-10 | 2023-10-05 | Nucorion Pharmaceuticals, Inc. | Phosphor(n)amidatacetal and phosph(on)atalcetal compounds |
| US11427550B2 (en) | 2018-01-19 | 2022-08-30 | Nucorion Pharmaceuticals, Inc. | 5-fluorouracil compounds |
| MX428883B (es) * | 2019-04-22 | 2025-11-13 | Ligand Pharm Inc | Compuestos ciclicos de fosfato |
| WO2021011692A1 (en) | 2019-07-17 | 2021-01-21 | Nucorion Pharmaceuticals, Inc. | Cyclic deoxyribonucleotide compounds |
| EP4143199B1 (en) * | 2020-04-21 | 2025-11-19 | Ligand Pharmaceuticals, Inc. | Nucleotide prodrug compounds |
| WO2021216431A1 (en) * | 2020-04-21 | 2021-10-28 | Ligand Pharmaceuticals, Inc. | Benzyloxy phosph(on)ate compounds |
| JP7699205B2 (ja) * | 2020-10-21 | 2025-06-26 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 抗ウイルスプロドラッグ化合物 |
| US20240294565A1 (en) * | 2021-05-17 | 2024-09-05 | Ligand Pharmaceuticals Incorporated | Unnatural configuration nucleotide prodrug compounds |
| CN118005694B (zh) * | 2023-01-06 | 2025-04-22 | 北京双鹤润创科技有限公司 | 一种环状核苷类似物及其制备方法和应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013177195A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphate prodrugs for hcv infection |
| WO2019027905A1 (en) | 2017-07-31 | 2019-02-07 | January Therapeutics, Inc. | ORGANOPHOSPHATE DERIVATIVES |
| WO2019143860A1 (en) | 2018-01-19 | 2019-07-25 | Nucorion Pharmaceuticals, Inc. | 5-fluorouracil compounds |
| WO2019169323A1 (en) | 2018-03-02 | 2019-09-06 | January Therapeutics, Inc. | Nanoparticle compositions |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6023120B2 (ja) * | 1979-08-13 | 1985-06-05 | キッコーマン株式会社 | アデノシン−3′,5′−環状リン酸アルキルトリエステルの製造法 |
| DE3027279A1 (de) * | 1980-07-18 | 1982-05-06 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Substituierte adenosin-3',5'-phosphorsaeurebenzyltriester, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US5866548A (en) * | 1993-04-09 | 1999-02-02 | The Regents Of The University Of California | Caged membrane-permeant inositol phosphates |
| US5693521A (en) * | 1993-04-09 | 1997-12-02 | The Regents Of The University Of California | Membrane-permeant second messengers |
| US5834436A (en) * | 1993-04-09 | 1998-11-10 | The Regents Of The University Of California | Membrane-permeant second messengers |
| WO2007027248A2 (en) * | 2005-05-16 | 2007-03-08 | Valeant Research & Development | 3', 5' - cyclic nucleoside analogues for treatment of hcv |
| US8173621B2 (en) * | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| US8772474B2 (en) * | 2010-12-22 | 2014-07-08 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
| ES2674980T3 (es) * | 2012-10-08 | 2018-07-05 | Idenix Pharmaceuticals Llc | Análogos de 2'-cloro nucleósidos para infección por VHC |
| JP2016501200A (ja) * | 2012-11-19 | 2016-01-18 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | ウイルス性疾患を処置するための2−アルキニル置換ヌクレオシド誘導体 |
| US9243022B2 (en) * | 2012-12-21 | 2016-01-26 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EP3131914B1 (en) * | 2014-04-16 | 2023-05-10 | Idenix Pharmaceuticals LLC | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
| EP3471737B1 (en) * | 2016-06-20 | 2025-06-04 | Merck Sharp & Dohme LLC | Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases |
| MX428883B (es) * | 2019-04-22 | 2025-11-13 | Ligand Pharm Inc | Compuestos ciclicos de fosfato |
-
2020
- 2020-04-21 MX MX2021012894A patent/MX428883B/es unknown
- 2020-04-21 AU AU2020263283A patent/AU2020263283B2/en active Active
- 2020-04-21 JP JP2021559729A patent/JP7661235B2/ja active Active
- 2020-04-21 KR KR1020267009794A patent/KR20260062967A/ko active Pending
- 2020-04-21 CA CA3136954A patent/CA3136954A1/en active Pending
- 2020-04-21 US US17/604,681 patent/US20220220145A1/en active Pending
- 2020-04-21 EP EP20796308.3A patent/EP3966221A4/en active Pending
- 2020-04-21 WO PCT/US2020/029149 patent/WO2020219464A1/en not_active Ceased
- 2020-04-21 KR KR1020217037884A patent/KR20210154229A/ko not_active Ceased
- 2020-04-21 CN CN202080038544.0A patent/CN113939526A/zh active Pending
-
2025
- 2025-04-02 JP JP2025060882A patent/JP2025106352A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013177195A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphate prodrugs for hcv infection |
| WO2019027905A1 (en) | 2017-07-31 | 2019-02-07 | January Therapeutics, Inc. | ORGANOPHOSPHATE DERIVATIVES |
| WO2019143860A1 (en) | 2018-01-19 | 2019-07-25 | Nucorion Pharmaceuticals, Inc. | 5-fluorouracil compounds |
| WO2019169323A1 (en) | 2018-03-02 | 2019-09-06 | January Therapeutics, Inc. | Nanoparticle compositions |
Non-Patent Citations (12)
| Title |
|---|
| Biochem. Biophys. Res. Commun.,1973年,55,1072-1077 |
| Bioorg. Med. Chem. Lett.,2010年,20,7376-7380 |
| Bioorg. Med. Chem. Lett.,2012年,22,5924-5929 |
| J. Am. Chem. Soc.,1990年,112,7475-7482 |
| J. Biol. Chem.,1986年,261,15995-15999 |
| J. Biol. Chem.,1993年,268,6316-6322 |
| J. Chem. Inf. Model.,2005年,45,1101-1108 |
| J. Med. Chem.,1986年,29,1243-1249 |
| J. Org. Chem.,2002年,67,8063-8071 |
| REGISTRY(STN)[online],2017年,CAS 登録番号:2092994-09-5 |
| Tetrahedron Lett.,1975年,21,1661-1664 |
| Tetrahedron,1984年,40,2405-2414 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3136954A1 (en) | 2020-10-29 |
| JP2025106352A (ja) | 2025-07-15 |
| MX2021012894A (es) | 2021-11-17 |
| EP3966221A1 (en) | 2022-03-16 |
| WO2020219464A1 (en) | 2020-10-29 |
| JP2022529321A (ja) | 2022-06-21 |
| KR20260062967A (ko) | 2026-05-07 |
| CN113939526A (zh) | 2022-01-14 |
| KR20210154229A (ko) | 2021-12-20 |
| AU2020263283B2 (en) | 2026-04-23 |
| MX428883B (es) | 2025-11-13 |
| US20220220145A1 (en) | 2022-07-14 |
| AU2020263283A1 (en) | 2021-12-16 |
| EP3966221A4 (en) | 2023-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025106352A (ja) | 環状リン酸エステル化合物 | |
| TWI838355B (zh) | 5-氟尿嘧啶化合物 | |
| US10435429B2 (en) | 5-fluorouridine monophosphate cyclic triester compounds | |
| JP7181938B2 (ja) | ホスホロ(ン)アミダートアセタールおよびホスファ(ホナ)ートアルセタール化合物 | |
| CN115605492B (zh) | 核苷酸前药化合物 | |
| JP7699205B2 (ja) | 抗ウイルスプロドラッグ化合物 | |
| JP2026032020A (ja) | ベンジルオキシリン酸エステル(ホスホン酸エステル)化合物 | |
| WO2022245584A1 (en) | Unnatural configuration nucleotide prodrug compounds | |
| JP7625542B2 (ja) | 環状デオキシリボヌクレオチド化合物 | |
| RU2836016C2 (ru) | Циклические дезоксирибонуклеотидные соединения | |
| RU2796403C2 (ru) | Фосфор(n)амидатацетальные и фосф(он)атацетальные соединения | |
| HK40108726A (en) | Phosphor(n)amidatacetal and phosph(on)atalcetal compounds | |
| US20250188111A1 (en) | Cyclic phosphoramidate compounds | |
| HK40063264A (en) | Cyclic deoxyribonucleotide compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230418 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230418 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230726 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240513 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240808 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241108 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241216 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250306 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250402 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7661235 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |